J02AB02 · Anti-infectives for systemic use
Ketoconazole Esteve (previously Ketoconazole HRA)
Indications
Ketoconazole Esteve is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years.
Composition
- Active substance
- Ketoconazole
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ketoconazole Esteve (previously Ketoconazole HRA)
- Active substance
- Ketoconazole
- ATC code
- J02AB02
- Therapeutic area
- Cushing Syndrome
- Marketing authorisation holder
- Esteve Pharmaceuticals, S.A.
- Status
- Authorised
- EU authorisation